Functional analysis of CD14+HLA-DR−/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma

Chen, Yun; Pan, Guichang; Tian, Dan; Zhang, Yifei; Li, Taoping

doi:10.3892/ol.2017.6146

Cited by 8 publications

(5 citation statements)

References 31 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the impact of smoking was seldom considered. A high variability in the reported frequency of HLA-DR low MDSC in blood is striking: Vetsika and co-authors reported 25·2 ± 2% of HLA-DR low monocytes without any difference between NSCLC patients and controls [32], Huang and co-authors found 9·4% HLA-DR low monocytes in the blood of 89 NSCLC patients [33] and Chen and co-authors reported 7·7% HLA-DR low monocytes in patients with squamous cell carcinoma [34]. The latter value matches well with the 8·1% HLA-DR low MDSC of our small patient subgroup with squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Blood immune cell biomarkers in lung cancer

Riemann

Cwikowski

Turzer

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary Characterization of host immune cell parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. We monitored blood immune cells from 58 patients with non‐small‐ cell lung cancer (NSCLC) undergoing surgery of the primary tumor and from 50 age‐matched healthy volunteers. Complete leukocyte blood count, the number of circulating dendritic cells (DC), HLA‐DRlow monocytes and several lymphocytic subpopulations were determined by eight‐color flow cytometry. Furthermore, the prognostic value of the immune cell parameters investigated was evaluated by patients’ survival analysis. Compared to the control group, blood of NSCLC patients contained more neutrophils resulting in a higher neutrophil‐to‐lymphocyte ratio (NLR), but a lower number of blood DC, in particular of plasmacytoid DC (pDC), natural killer (NK) cells and naive CD4+ and CD8+ T cells. Furthermore, a higher frequency of CD4+ regulatory T cells (Treg) and HLA‐DRlow monocytes was detected, and smoking had a significant impact on these values. HLA‐DRlow monocytes were positively correlated to the number of neutrophils, monocytes and NLR, but negatively associated with the number of pDC and naive CD4+ T cells. The frequency of Treg, HLA‐DRlow monocytes and naive CD4+ and CD8+ T cells as well as the ratios of CD4/HLA‐DRlow monocytes and HLA‐DRlow monocytes/pDC correlated with patient’s overall survival. Next to Treg, HLA‐DRlow monocytes and naive T cells represent prognostic markers for NSCLC patients and might be useful for monitoring of patients’ responses to immunotherapies in future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood immune cell biomarkers in lung cancer

Riemann

Cwikowski

Turzer

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…The emergency myelopoiesis described in patients with COVID‐19 [ 22 , 25 , 64 ] indicates that expansion of M‐MDSCs may occur in the bone marrow. M‐MDSCs can be identified as CD14+HLA‐DR –/lo cells [ 80 , 81 , 82 ], and may therefore not always be distinguished from CMs. Several cytokines could be involved in the expansion of M‐MDSCs during COVID‐19, including IL‐6 and IL‐10 [ 83 ].…”

Section: M‐mdscs Are Expanded In Circulation During Acute Covid‐19mentioning

confidence: 99%

Respiratory and systemic monocytes, dendritic cells, and myeloid‐derived suppressor cells in COVID‐19: Implications for disease severity

2022

View full text Add to dashboard Cite

Since the beginning of the SARS‐CoV‐2 pandemic in 2020, researchers worldwide have made efforts to understand the mechanisms behind the varying range of COVID‐19 disease severity. Since the respiratory tract is the site of infection, and immune cells differ depending on their anatomical location, studying blood is not sufficient to understand the full immunopathogenesis in patients with COVID‐19. It is becoming increasingly clear that monocytes, dendritic cells (DCs), and monocytic myeloid‐derived suppressor cells (M‐MDSCs) are involved in the immunopathology of COVID‐19 and may play important roles in determining disease severity. Patients with mild COVID‐19 display an early antiviral (interferon) response in the nasopharynx, expansion of activated intermediate monocytes, and low levels of M‐MDSCs in blood. In contrast, patients with severe COVID‐19 seem to lack an early efficient induction of interferons, and skew towards a more suppressive response in blood. This is characterized by downregulation of activation markers and decreased functional capacity of blood monocytes and DCs, reduced circulating DCs, and increased levels of HLA‐DR lo CD14 + M‐MDSCs. These suppressive characteristics could potentially contribute to delayed T‐cell responses in severe COVID‐19 cases. In contrast, airways of patients with severe COVID‐19 display hyperinflammation with elevated levels of inflammatory monocytes and monocyte‐derived macrophages, and reduced levels of tissue‐resident alveolar macrophages. These monocyte‐derived cells contribute to excess inflammation by producing cytokines and chemokines. Here, we review the current knowledge on the role of monocytes, DCs, and M‐MDSCs in COVID‐19 and how alterations and the anatomical distribution of these cell populations may relate to disease severity.

show abstract

“…Chen et al investigated CD14 + HLA-DR -/low MDSC frequency in blood samples of almost 80 patients with squamous type of LC (Sq NSC-LC) (21). They also demonstrated that LC patients had significanlty increased number comparing to healthy controls, and that MDSC number gradually rise in those patients with higher TNM stage.…”

Section: Discussionmentioning

confidence: 99%

Significance of myeloid-derived suppressor cells (MDSCs) like CD14+B7-H4 cells frequency in blood and tumor microcirculation of lung cancer patients

Vuković

Karlicic

Ristić³

et al. 2021

VOJNOSANIT PREGL

View full text Add to dashboard Cite

Background/Aim. Myeloid-derived suppressor cells (MDSCs) suppress immune responses via a series of inhibitory mechanisms, which ultimately could lead to tumor growth. B7-H4 expression is significantly associated with poor outcome and promotion of tumor cell proliferation, invasion and migration in patients with various cancers. Data concerning B7-H4 expression in lung cancers (LC), either on tumor or immunological cells, are still sporadic. The aim was to estimate and correlate the number of CD14+B7-H4+MDSCs in blood and lung tumor microcirculation with clinical stage, histology type of tumor, tumor node metastasis (TNM) stadium, nodal status and disease outspread. Methods. The study included 44 lung cancer patients (III and IV clinical stage) and 30 healthy controls. CD14+B7-H4+ MDSC number was estimated by flow cytometry in blood and tumor microcirculation samples of each patient. Results. CD14+B7-H4+ MDSCs number was significantly higher in patients? samples compared to controls. CD14+B7-H4+ MDSC number was significantly increased in tumor compared to blood sample of the same patient. Clinical stage III patients had the increased number of the CD14+B7-H4+ MDSC compared to stage IV, in both types of samples. According to histology, small cell lung cancer (SCLC) patients had the highest average CD14+B7-H4+ MDSCs number, significantly increased compared to patients with squamous and large cell LC histology type. Tumor size was directly associated with the number of the CD14+B7-H4+ MDSC, both in blood and tumor samples. Furthermore, nodal involvement was associated with the gradual increase of the CD14+B7-H4+ MDSC number, being the highest in the N3 group, again both in blood and tumor samples. Finally, we detected higher CD14+B7-H4+ MDSCs number in the samples of patients without metastases. Conclusion. CD14+B7-H4+ MDSCs n umber in L C patients is significantly associated with tumor histology type, lymph node involvement, disease extent degree and tumor size. Concerning their large number in LC tumor microenvironment together with immunosuppressive capacities, CD14+B7-H4+ MDSCs could represent important tumor promoting factor in LC pathophysiology.

show abstract

Functional analysis of CD14+HLA-DR−/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma

Cited by 8 publications

References 31 publications

Blood immune cell biomarkers in lung cancer

Blood immune cell biomarkers in lung cancer

Respiratory and systemic monocytes, dendritic cells, and myeloid‐derived suppressor cells in COVID‐19: Implications for disease severity

Significance of myeloid-derived suppressor cells (MDSCs) like CD14+B7-H4 cells frequency in blood and tumor microcirculation of lung cancer patients

Contact Info

Product

Resources

About